OBJECTIVES: To examine how the slimming drug, Letigen 1 , containing ephedrine (E) 20 mg and caffeine (C) 200 mg (E C), affects blood pressure in normotensive and hypertensive patients treated with adrenergic b-receptor blocking drugs and/or other antihypertensive agents, during a period of six weeks. DESIGN: A double-blind, randomised, placebo controlled study of ®ve parallel groups of overweight patients from general practices. SUBJECTS: One hundred and thirty-six patients with Body Mass Index (BMI) b 25 kg/m 2 were included consecutively by 25 general practitioners in Denmark and randomized into ®ve groups: (1) Hypertensive patients treated with betablockers and E C; (2) Hypertensive patients treated with antihypertensive agents other than betablockers, and E C; (3) Normotensive patients treated with E C; (4) Hypertensive patients under any antihypertensive treatment placebo; and (5) Normotensive patients placebo. All patients were instructed in a 1200 kcal ( 5040 kj) diet. RESULTS: Of a total of 136 patients aged 20±74 y, 112 completed the study protocol. Fluctuations in systolic and diastolic blood pressure were seen in all groups. The systolic blood pressure was reduced signi®cantly (5.5 mmHg) in the patients treated with antihypertensive agents other than betablockers, plus E C. In the other hypertensive groups the reduction in blood pressure was not signi®cant. In normotensive patients treated with E C, the systolic and the diastolic blood pressure declined signi®cantly (4.4/3.9 mmHg). At the end of the treatment period heart rate had increased signi®cantly (4.9 beats/min) in the group of normotensive patients treated with E C. Blood pressure and heart rate measured by the patient at home showed similar¯uctuations from baseline prior to and during treatment with E C or placebo.
Introduction
More than half of the patients suffering from hypertension are overweight. 1 The primary management of hypertension comprises non-pharmacologic therapy including slimming. It is dif®cult for some patients to lose weight on diet alone, and therefore additional therapy with anorectic agents is a possibility. In Denmark two centrally stimulating antiobesity drugs, (amphepramone (Dobesin 1 and Regenon
1
) and a mixture of ephedrine and caffeine (E C Letigen 1 ), and two non-stimulating antiobesity drugs, dexfen¯uramine (Isomeride 1 ) and fen¯ura-mine (Ponderal 1 ), are available. It has been shown that E C combined with diet causes a signi®cantly greater loss of weight than diet alone. 2 Ephedrine is an agonist of a-receptors as well as breceptors. 3 Some studies have shown that ephedrine may cause a rise in the systolic blood pressure (BP) and heart rate (HR) 4 , while in other studies no rise was detected. 5 Adrenergic b-receptor antagonists (betablockers) are used to treat hypertension, but the concomitant intake of ephedrine might prevent a reduction in BP. On this basis we wanted to examine whether the BP or HR would be affected by E C in overweight normotensive people and in overweight well-regulated hypertensive patients treated with or without betablockers.
Methods

Study design
The study was designed as a double-blind, randomised, placebo controlled study of parallel groups of overweight patients from general practices. The patients were recruited by 25 general practitioners (GPs, see Acknowledgements, for a list). The patients were included consecutively and treated for six weeks.
Patients
Overweight male and female patients aged 18±74 y. The inclusion criteria were (1) Body Mass Index (BMI) b 25 kg/m 2 ; (2) normotension or hypertension well-regulated by drug treatment plus; (3) informed consent. The exclusion criteria were (1) pregnancy, desire for pregnancy, or breast-feeding; (2) signi®cant heart failure and/or moderate to severe ischaemic heart disease; (3) endocrine diseases requiring treatment; (4) allergy to ephedrine and/or caffeine; (5) treatment with monoamine oxidase inhibitors 14 d prior to onset of treatment with the study drug; (6) treatment with anorexigenic agents during the last month; (7) other serious diseases, psychogenic or somatic, in which case participation in the study might induce risks to the patient; and (8) other conditions making patients unsuitable for participation.
Randomisation
The included patients were unequally randomised in the ratio of three E C treated patients to two placebo treated patients by strati®ed randomisation, forming the following ®ve groups: Group 1: E C treated hypertensive patients well-regulated on betablockers (diastolic BP`100 mmHg during the last three months). Group 2: E C treated hypertensive patients well-regulated on antihypertensive agents other than betablockers. Group 3: E C treated normotensive patients without antihypertensive drugs and with a diastolic BP 90 mmHg during the last three months. Group 4: Placebo treated hypertensive patients wellregulated (diastolic BP`100 mmHg during the last three months) with betablockers and/or other antihypertensive agents. Group 5: Placebo treated normotensive people without antihypertensive drugs and a diastolic BP 90 mmHg.
Information
The participants were informed in detail about the study and written informed consent was obtained. The study was conducted according to the principles of the declaration of Helsinki II and was approved by the local ethical committee.
Study schedule
BP and HR were measured at home two to three times daily during the week prior to onset of treatment (week 0) and during the ®rst week of treatment (week 1). This close monitoring at home during the ®rst week of treatment was used to provide data on very acute effects if any. BP, HR and weight were measured at the general practice one week prior to onset of treatment, on day 1 of each week of treatment, and on day 1 after discontinuation of treatment. Table 1 shows the trial schedule.
Diet
On the day of treatment initiation, all patient were carefully instructed in a diet of 1200 kcal ( 5040 kj) per day. 
Concomitant medication
Anorexic drugs or monoamino oxidase inhibitors were not permitted during the trial while other chronic therapy including antihypertensives continued unchanged.
Demographic data
The following demographic data were recorded: Date of birth, sex, height, and weight. History of obesity and dietary habits were discussed as part of the diet instructions. The patients were questioned about antihypertensive treatment and the use of other drugs.
Measurement of BP and HR
In the GPs of®ce BP was measured by means of a mercury sphygmomanometer with adjusted cuff according to the guidelines stated by WHO. 6 BP was measured in the sitting position after ®ve minutes' rest on the arm which had the highest BP initially. The diastolic BP was measured as the phase 5 Korotkoff sound. The pulse of the radial Is an ephedrine caffeine treatment contraindicated in hypertension? J Ingerslev et al artery was counted for 15 s. BP was measured by the GP one week prior to onset of treatment, day 1 of each week of treatment, and day 1 after discontinuation of treatment. The patients were instructed how to use a fully automatic BP unit (Takeda UA 751) for home BP and HR monitoring.
For the values measured by the GPs, baseline of BP and HR was calculated as a mean of measurements one week prior to and immediately before treatment.
The baseline values for the patient measurements were calculated as a mean of all measurements in the week prior to onset of treatment. The maximum rise of the systolic and diastolic BP and HR during the period of treatment, named BP max±diff and HR max±diff respectively, was de®ned as the maximum difference to baseline recorded during the period of treatment. BP max±diff expresses the risk to which the cardiovascular system is exposed.
Weight
The patients were weighed each week (Table 1) dressed but without outdoor clothing and footwear.
Tolerance
At each visit to the GP the patient was asked if the drug had caused discomforts. The nature, duration, and intensity were elaborated.
Excluded patients
Patients were withdrawn if the diastolic BP rose to 115 mmHg, and in case of unacceptable adverse reactions.
Statistical method
Descriptive analyses were used for demographic data, which are presented as mean values AE standard deviations or range. Pre-study calculations showed that twenty-two patients in each group were needed in order to detect a difference in BP of 5 mmHg with a level of signi®cance of 0.05 for type I error and 0.20 for type II error. Effect data were analysed by parametric analysis of variance. Drug related complaints were tested by a w-square test or Fisher's exact test. Differences were considered signi®cant at Pvalues`0.05.
Results
Patients
One hundred and thirty-six patients were included in the study. Two patients were withdrawn at the second visit before the study medication was delivered. Within the ®rst week of treatment, a further seven patients were withdrawn. Fifteen patients were treated for less than ®ve weeks. The population included in the full protocol therefore comprised 112 patients. Home BP monitoring was performed by 103 patients. A total of 134 patients were included in the primary analysis of side-effects. Six patients treated with E C, and no placebo treated patient, were withdrawn due to sideeffects. The others were excluded for other reasons.
Demographic data
The patients included in the study comprised 87 women and 47 men, with a mean age of 49 y. The distribution of weight, height and Body Mass Index (BMI) in the groups appears in Table 2 .
As expected the mean age of the normotensive patients was lower than the age of the patients with hypertension. The male to female ratio differs among groups, but this was not expected to affect the results of the study. BMI is similar in groups while mean body weight differs. Table 3 shows the mean values of of®ce measured diastolic and systolic BP, HR, weight, and BMI before and at the end of treatment.
Patients in group 1 used betablockers mainly as monotherapy, in a few cases this was combined with other antihypertensive agents, mostly thiazide diuretics. Beta-1-selective blockers were used in 85% of the cases. In group 2, 45% of the patients used angiotensin converting enzyme (ACE) inhibitors, 27% calcium channel blockers and 20% diuretics.
BP measurements
The systolic BP was reduced signi®cantly (P 0.037) in the hypertensive group treated with antihypertensive agents other than betablockers, plus E C. In the other hypertensive groups, BP did not change signi®-cantly. In the normotensive group tested with E C both systolic and diastolic BP were reduced signi®-cantly (P 0.009 systolic, P 0.013 diastolic). Table   Table 2 Demographhic data at the start of the study for 134 obese patients Is an ephedrine caffeine treatment contraindicated in hypertension? J Ingerslev et al 4 shows the maximum difference (max±diff) in systolic and diastolic BP during the period of treatment.
It was signi®cant for all of the groups, apart from the diastolic BP in normotensive patients treated with E C (P 0.0505). The BP max±diff did not differ signi®cantly between the groups. The average systolic and diastolic of®ce BP differences during treatment are shown in Figures 1 and 2 . None of the patients experienced diastolic BP b 115 mmHg.
Home BP monitorings Table 5 shows BP measured at home one week before and during the ®rst week of treatment. There was no signi®cant differences between the two weeks. The BP max±diff values during week 1 were not higher than pretreatment values, Table 6 .
Heart rate
Only in the normotensive patients receiving E C did the HR increase signi®cantly by an average of 4.9 beats per minute ( Table 3 ). The HR max±diff was signi®cant in all groups (Table 4 ). The home recorded HR in the ®rst week of treatment did not differ signi®cantly from HR the week before treatment ( Table 5 ). The HR max±diff in week 1 was not higher than in week 0 ( Table 6 ). The average HR differences during the study are shown in Figure 3 . Is an ephedrine caffeine treatment contraindicated in hypertension? J Ingerslev et al
Weight
The loss of weight and decline in BMI were signi®-cant in all groups and higher in the E C treated groups not receiving betablockers, but the difference between groups was not statistically signi®cant, Table 3 .
Side-effects
In the E C treated groups 45 (56%) of the 81 patients had side-effects: Nausea (12%), palpitations (10%), increased perspiration (6%), and tremor (5%). In the placebo group 11 (21%) of 53 patients had sideeffects, mainly palpitations (6%) and nausea (4%).
The difference between the E C and the placebo group was signi®cant (P 0.002). No serious adverse events occurred.
Discussion
As more than half of those people with hypertension are overweight, 1 and as overweight affects the cardiovascular system, 7, 8, 9 slimming is an appropriate therapy. Non-pharmacological therapy should always be considered for management of mild to moderate hypertension. Sometimes anorexic drugs, e.g. Is an ephedrine caffeine treatment contraindicated in hypertension? J Ingerslev et al E 10 C, should be considered too. Loss of weight results in systolic and diastolic BP reduction of approximately one mmHg per kg weight loss as shown by Reisin et al 7 and con®rmed in our study. Taskin et al 4 reported ephedrine to cause a mild rise in the systolic BP. A study performed by Astrup et al 11 showed that ephedrine may cause a mild, acute rise in BP, while in another study the same authors found no effect on systolic or diastolic BP. 2 The antihypertensive effect of betablockers is presumably mediated through b-adrenergic receptors. Thus, ephedrine might theoretically eliminate this antihypertensive effect. Additionally, ephedrine may cause a mild to moderate degree of an amphetaminelike stimulation of the central nervous system resulting in symptoms like agitation, anxiety, insomnia, tremor, and respiratory stimulation. Usually, the discomforts are transient as tolerance is acquired. This corresponds to the side-effects observed in our study.
Caffeine is a methyl xanthine derivative found in coffee, tea, chocolate, and coca-cola. The pharmacologic effects of caffeine are bronchodilatation, cardiac stimulation, and diuresis. 12 After the administration of 250 mg caffeine to 18, caffeine abstaining, healthy people Robertson et al 13 found an immediate mean rise in systolic BP of 11 mmHg and in diastolic BP of 6±7 mmHg. The HR increased by 6±7 beats per minute in the placebo group as well as in the caffeine group. Furthermore they reported an episode with paroxysmal atrial tachycardia after administration of 250 mg caffeine in a patient with four previous episodes of tachycardia with no relation to caffeine. After administration of caffeine t.i.d. for a few days, tolerance was acquired. Thus there was no long-lasting effect on either pulse or BP.
Astrup et al 14 did not ®nd signi®cant changes in either BP or pulse after administration of 200 mg caffeine, whereas 400 mg caffeine resulted in systolic BP rises of 6.3 mmHg on average.
In long term studies of the E C combination, Astrup et al 2 and Breum et al, 16 studied the effects on the cardiovascular system. They found declining diastolic and systolic BP and unchanged or slightly increased HR during a period of 24 weeks and 15 weeks respectively.
In contrast, the purpose of this study was to evaluate possible risks of developing hypertension or tachycardia in normotensive patients, or of reducing the effect of an antihypertensive treatment administered to well-regulated hypertensive patients with or without betablockers.
The study was designed with a rapid increase of E C dose over three days contrary to the recommended one to two weeks. The rapid increase should permit easy detection of possible early rises in BP or HR.
During the ®rst week of treatment the home monitorings of BP and HR did not show any increase compared to the week before treatment. Therefore, it Table 6 Average maximum differences in home measured systolic blood pressure, diastolic blood pressure and heart rate between means during the week prior to therapy (week 0) and single measurements during week 0 and during the ®rst week of treatment (week 1) Is an ephedrine caffeine treatment contraindicated in hypertension? J Ingerslev et al may be concluded that the treatment with E C had no effect on BP or HR during the ®rst week of treatment. During the treatment period of six weeks the systolic BP was reduced signi®cantly in the non betablocked hypertensive group treated with E C, and the normotensive group treated with E C had a signi®cant fall in systolic as well as diastolic BP.
Thus, E C did not increase BP in either normotensive or hypertensive patients during short term treatment. The BP max±diff was not signi®cantly different between groups, which means that the BP changes measured during treatment were similar in the active and the placebo treated groups. In the betablocker treated hypertensive group the BP was unchanged during treatment. Based on pharmacological considerations the combination of E C and betablocker seems inappropriate. Nevertheless E C did not counteract the antihypertensive effect of betablockers. In a case report Just and Bruun, 15 described a dramatic BP rise to 250/120 mmHg in a 24 year old man who had taken ®ve`Elsinore-pills' daily for four days, each pill containing 20 mg ephedrine and 50 mg caffeine. The symptoms were oppression in the chest, palpitation, headache, and vertigo. An increased vascular reactivity was suspected by the authors, but an anxiety reaction in a person suffering from whitecoat hypertension might also be an explanation. In the E C treated patients in our study no similar reactions were found.
During the ®rst week of treatment no signi®cant differences between the groups were detected in home measured HR. During the following six weeks a signi®cant increase in HR (4.9 beats per minute) was demonstrated in the normotensive group treated with E C which probably is due to the pharmacological effect of E C . No signi®cant change in HR was seen in the hypertensive patients. This may be explained by concomitant treatment with antihypertensive drugs.
During the treatment period of six weeks signi®cant loss of weight was seen in all groups but there were no signi®cant differences between the placebo groups and the E C groups. It should be stressed that the purpose of this study was not to examine weight loss, but primarily to determine the effects on HR and BP. From previous studies, among others Astrup et al 2 it is known that the period of treatment must be at least three months to achieve a signi®cantly higher weight loss using E C compared with placebo.
In the present study, side-effects were experienced in 21% of the placebo group and in 56% of the E C group but only six patients (7%), all from the E C group, were withdrawn from the study because of side-effects. Astrup et al 2 found that side-effects occurred in 47% in the group treated with E C but the side-effects had declined after treatment for four weeks. In the placebo group 7±8% had side-effects. In a study performed by Breum et al 16 54% of the E C treated patients experienced side-effects and six out of 50 E C treated patients (12%) were withdrawn for this reason. The side-effects declined rapidly after the ®rst week of treatment. In the reported studies the patients were on full dosage from day 3±4 as in our study. The slow dose increment recommended today should reduce discomforts at the beginning of the treatment.
Conclusions
The study did not support the assumption that E C would cause signi®cant BP rises in normotensive, or well-treated hypertensive, obese patients, either at the beginning of the treatment or after six weeks of treatment. The anti-hypertensive effect of betablockers was not impaired by E C.
